Back to top

Judah Frommer Maintains Hold on LKFT, Citing Early but Strategic Gamgertamig Acquisition and Limited Economic Upside

Morgan Stanley analyst Judah Frommer maintained a Hold rating on Lakefront Biotherapeutics today and set a price target of $30.00. Judah Frommer ha...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Lakefront Biotherapeutics - Sponsored ADR (LKFT)